Results for tag: "Revefenacin"

Revefenacin is a long-acting muscarinic antagonist (LAMA) bronchodilator used to treat chronic obstructive pulmonary disease (COPD). It is administered as an inhalation solution and works by relaxing the airways to improve breathing. Revefenacin is a relatively new drug, approved by the US Food and Drug Administration (FDA) in 2019. It is the first and only LAMA bronchodilator to be approved for once-daily dosing. Revefenacin is part of a larger market of respiratory drugs, which includes bronchodilators, anti-inflammatory agents, and combination therapies. Bronchodilators are the most commonly prescribed drugs for COPD, and LAMAs are the most effective type. Revefenacin is the only LAMA bronchodilator approved for once-daily dosing, which makes it an attractive option for patients. Some companies in the Revefenacin market include Sunovion Pharmaceuticals, Inc., which manufactures and markets the drug, and Mylan N.V., which has the rights to market and distribute the drug in the US. Other companies in the market include Teva Pharmaceuticals, which has the rights to market and distribute the drug in Europe, and Hikma Pharmaceuticals, which has the rights to market and distribute the drug in the Middle East and North Africa. Show Less Read more